NSE ScannerMedical Devices & Supplies · Medical Specialties · NSE: MOLBIO · data 2026-10-31
Molbio Diagnostics Limited
In plain words
Price: 24.5% below its 52-week high of ₹1,686.8.
Delivery: 19.6% of traded shares were kept for delivery over the last 10 sessions, against 17.8% over the last 52.
Latest results: a net profit of ₹59 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | 58.1% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 41.3%, pledged 0.0%, institutions 20.7%.
ROE 13.8%, ROCE 19.2%: how much profit it earns on the money it uses.
Debt/equity 0.30, Profit growth — and sales growth 58.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Latest results in brief (Q1 FY27)
MOLBIO Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹408.38 crore.
Net profit was ₹58.75 crore.
Operating margin was 24.6%.
EPS was ₹5.21.
MOLBIO के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹408.38 करोड़।
शुद्ध मुनाफ़ा: ₹58.75 करोड़।
ऑपरेटिंग मार्जिन: 24.6%।
EPS: ₹5.21।
MOLBIOના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹408.38 કરોડ.
ચોખ્ખો નફો: ₹58.75 કરોડ.
ઓપરેટિંગ માર્જિન: 24.6%.
EPS: ₹5.21.
Written from the filed numbers. Not a recommendation.
Smart-money activity
28/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 14.6% over the last 20 sessions vs 15.0% in the 40 before (0.97x); shares delivered per day 0.45x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 7/20: Net +₹20.72 cr bought in bulk/block deals over 90 days (0.08x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 9/15: 0 insider buy days (promoter group among them) and 2 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 4 schemes hold it, about ₹179 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Deal ● Results
- 29 Oct 26Insider SAST disclosure: Kotak Mahindra Mutual Fund acquired 5,70,000 shares -2.9% next session
- 28 Oct 26Insider SAST disclosure: Kotak Mahindra Mutual Fund acquired 5,70,000 shares +2.9% next session
- 11 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED bought ₹20.72 cr -10.1% next session
- 5 Sept 26Results Q1 FY27 results: net profit ₹58.8 cr -2.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹408 cr | ₹59 cr | — | 24.6% | 5.21 |
Shareholding trend
| Holder | Sept 2026 |
|---|---|
| Promoters | 41.29% |
| Foreign institutions (FII) | 1.59% |
| Domestic institutions (DII) | 19.08% |
| Mutual funds | 8.03% |
| Retail investors | 2.96% |
| Number of shareholders | 50,395 |
Common questions
What was Molbio Diagnostics Limited's latest quarterly profit?
Molbio Diagnostics Limited reported a net profit of ₹59 cr for the quarter ended Jun 2026, on revenue of ₹408 cr.
How much do promoters hold in Molbio Diagnostics Limited?
Promoters held 41.29% of Molbio Diagnostics Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Molbio Diagnostics Limited debt-free?
Its latest reported debt-to-equity ratio is 0.3.
What is the 52-week high and low of Molbio Diagnostics Limited?
The 52-week high is ₹1,686.8 and the 52-week low is ₹807.
Mutual funds holding Molbio Diagnostics Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 4 schemes holding about ₹179 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 1.77% | ₹62 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 0.54% | ₹50 cr |
| Mirae Asset Flexi Cap Fund | Mirae Asset Mutual Fund | 1.05% | ₹46 cr |
| Nippon India Innovation Fund | Nippon India Mutual Fund | 0.73% | ₹21 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics Limited | ₹1,274 | ₹14,689 cr | — | — | 13.8% | 19.2% | 0.3 | +57.9% |
| Lenskart Solutions Limited | ₹678.2 | ₹1,17,960 cr | 179 | — | 6.7% | 7.8% | 0.35 | +68.7% |
| Poly Medicure Limited | ₹1,449.5 | ₹14,676 cr | 46.7 | — | 11% | 10.9% | 0.11 | -26.5% |
| Standard Engineering Technology Ltd | ₹395.85 | ₹7,885 cr | 92.3 | — | 10.7% | 13.3% | 0.1 | +115.7% |
| Sahajanand Medical Technologies Limited | ₹462.7 | ₹4,675 cr | — | — | — | — | — | +24.7% |
| Virtuoso Optoelectronics Limited | ₹460.2 | ₹1,575 cr | 83.5 | — | 4.3% | -3.5% | 0.84 | +2.3% |
Compare MOLBIO with LENSKART in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MOLBIO in NSE Scanner →